{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-056664","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.611518+00:00","generated_at":"2026-06-02T23:18:44.908695+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AEON Biopharma Phase 2 trial of ABP-450 for chronic migraine fails primary endpoint","bullets":["Primary endpoint: mean reduction in monthly migraine days (MMD) at weeks 13-24 was 8.5 (150U), 7.7 (195U), 8.4 (placebo); p=0.9132 and 0.3611.","Trial did not achieve statistical significance for primary or any secondary endpoints; placebo response was unexpectedly higher than historical studies.","Company immediately commencing cash preservation measures and reviewing all strategic options for ABP-450 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-056664","json":"https://secwatch.observer/filing/0001104659-24-056664.json","markdown":"https://secwatch.observer/filing/0001104659-24-056664.md","text":"https://secwatch.observer/filing/0001104659-24-056664.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/0001104659-24-056664-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465924056664/tm2413422d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:18:44.908695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}